Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Advertisement

Advertisement




Jul
20
Today In Oncology
EMERALD-3 Shows Benefit With STRIDE Plus TACE in Hepatocellular Carcinoma
Study Finds Rising Breast Cancer Incidence Across Asian American, Native Hawaiian, and Pacific Islander Groups
Meta-Analysis Highlights Cardiovascular Safety Advantage of Second-Generation BTK Inhibitors
ctDNA Status May Predict Benefit From Adjuvant Chemotherapy After Resection of Colorectal Liver Metastases
Tumor Microenvironment Ecotypes May Explain Differences in Multiple Myeloma Outcomes
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo